TOBRADEX ST
LOE Approachingtobramycin / dexamethasone
NDAOPHTHALMICSUSPENSION/DROPS
Approved
Feb 2009
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
5/8 — Partial
TOBRADEX ST (tobramycin / dexamethasone) is corticosteroid hormone receptor agonists [moa]. Approved for inflammatory conditions of the palpebral, bulbar conjunctiva, cornea and 7 more indications. First approved in 2009.
Drug data last refreshed 7m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOBRADEX ST is a fixed-dose ophthalmic suspension combining tobramycin (antibiotic) and dexamethasone (corticosteroid) for topical ocular use. It treats inflammatory conditions of the anterior segment including conjunctivitis, uveitis, and corneal injury, working through corticosteroid receptor agonism to suppress inflammation while tobramycin provides antimicrobial coverage. The combination addresses both infection risk and inflammatory response in a single formulation.
$0.004BPart D
LOE Approaching2.1 years to LOEProduct is in late-stage lifecycle with modest Part D spending (~$4M annually, 13,756 claims in 2023) and 15 direct competitors, signaling a mature, competitive market with limited team expansion potential.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (10)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.